Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 17, 2022 - Issue
Submit an article Journal homepage
186
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial

David MG Halpin1 University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2009-4406View further author information
ORCID Icon,
Robyn Kendall2 ICON Health Economics, ICON plc, Vancouver, BC, CanadaORCID Iconhttps://orcid.org/0000-0001-6331-5497View further author information
ORCID Icon,
Soham Shukla3 Value Evidence and Outcomes, GSK, Collegeville, PA, USAORCID Iconhttps://orcid.org/0000-0002-4139-0856View further author information
ORCID Icon,
Alan Martin4 Value Evidence and Outcomes, GSK, Uxbridge, UKORCID Iconhttps://orcid.org/0000-0002-3673-3383View further author information
ORCID Icon,
Dhvani Shah5 ICON Health Economics, ICON plc, New York, NY, USAView further author information
,
Dawn Midwinter6 Biostatistics, GSK, Brentford, UKORCID Iconhttps://orcid.org/0000-0003-2434-1152View further author information
ORCID Icon,
Kai M Beeh7 Insaf Respiratory Research Institute, Wiesbaden, GermanyORCID Iconhttps://orcid.org/0000-0001-9067-118XView further author information
ORCID Icon,
Janwillem WH Kocks8 General Practitioners Research Institute, Groningen, the Netherlands;9 Observational and Pragmatic Research Institute, Singapore;10 Groningen Research Institute Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, Groningen, the Netherlands;11 Department of Pulmonology, University of Groningen, University Medical Center Groningen, Groningen, the NetherlandsORCID Iconhttps://orcid.org/0000-0002-2760-0693View further author information
ORCID Icon,
Paul W Jones12 Global Respiratory Franchise, GSK, Brentford, UKORCID Iconhttps://orcid.org/0000-0001-6087-9182View further author information
ORCID Icon,
Chris Compton12 Global Respiratory Franchise, GSK, Brentford, UKORCID Iconhttps://orcid.org/0000-0002-7564-5343View further author information
ORCID Icon,
Nancy A Risebrough13 ICON Health Economics, ICON plc, Toronto, ON, CanadaView further author information
&
Afisi S Ismaila3 Value Evidence and Outcomes, GSK, Collegeville, PA, USA;14 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, CanadaORCID Iconhttps://orcid.org/0000-0002-2876-8308View further author information
ORCID Icon show all
Pages 2745-2755 | Received 12 Apr 2022, Accepted 24 Sep 2022, Published online: 25 Oct 2022

References

  • NICE. Health and social care directorate. Quality standards and indicators. Briefing paper; 2015. Available from: https://www.nice.org.uk/guidance/qs10/documents/briefing-paper. Accessed August 2, 2021.
  • Trueman D, Woodcock F, Hancock E, British Lung Foundation. Estimating the economic burden of respiratory illness in the UK; 2017. Available from: https://www.blf.org.uk/policy/economic-burden. Accessed August 2, 2021.
  • GOLD. 2020 report; 2020. Available from: https://goldcopd.org/. Accessed August 2, 2021.
  • NICE. NICE guideline - chronic obstructive pulmonary disease in over 16s: diagnosis and management; 2019. Available from: https://www.nice.org.uk/guidance/ng115. Accessed August 2, 2021.
  • Yu AP, Guerin A, Ponce de Leon D, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ. 2011;14(4):486–496. doi:10.3111/13696998.2011.594123
  • van der Palen J, Moeskops-van Beurden W, Dawson CM, et al. A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:2515–2523. doi:10.2147/COPD.S169060
  • Sulku J, Bröms K, Högman M, et al. Critical inhaler technique errors in Swedish patients with COPD: a cross-sectional study analysing video-recorded demonstrations. NPJ Primary Care Respir Med. 2021;31(1):5. doi:10.1038/s41533-021-00218-y
  • Brennan V, Mulvey C, Costello RW. The clinical impact of adherence to therapy in airways disease. Breathe. 2021;17(2):210039. doi:10.1183/20734735.0039-2021
  • van Boven JF, Chavannes NH, van der Molen T, Rutten-van Molken MP, Postma MJ, Vegter S. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir Med. 2014;108(1):103–113. doi:10.1016/j.rmed.2013.08.044
  • Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017;49(2):1601794. doi:10.1183/13993003.01794-2016
  • Kocks JWH, Chrystyn H, van der Palen J, et al. Systematic review of association between critical errors in inhalation and health outcomes in asthma and COPD. NPJ Primary Care Respir Med. 2018;28(1):43. doi:10.1038/s41533-018-0110-x
  • Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
  • Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446. doi:10.1164/rccm.201703-0449OC
  • Albertson TE, Murin S, Sutter ME, Chenoweth JA. The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials. Pragmatic Observational Res. 2017;8:175–181. doi:10.2147/POR.S144157
  • Halpin DMG, Worsley S, Ismaila AS, et al. INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice. ERJ Open Res. 2021;7(2):00950–02020. doi:10.1183/23120541.00950-2020
  • Ismaila AS, Risebrough N, Schroeder M, et al. Cost-effectiveness of once-daily single-inhaler triple therapy in COPD: the IMPACT trial. Int J Chron Obstruct Pulmon Dis. 2019;14:2681–2695. doi:10.2147/COPD.S216072
  • Schroeder M, Benjamin N, Atienza L, et al. Cost-effectiveness analysis of a once-daily single-inhaler triple therapy for patients with chronic obstructive pulmonary disease (COPD) using the FULFIL trial: a Spanish perspective. Int J Chron Obstruct Pulmon Dis. 2020;15:1621–1632. doi:10.2147/COPD.S240556
  • Fenwick E, Martin A, Schroeder M, et al. Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK. ERJ Open Res. 2021;7(1):00480–2020. doi:10.1183/23120541.00480-2020
  • Schroeder M, Shah D, Risebrough N, et al. Cost-effectiveness analysis of a single-inhaler triple therapy for patients with advanced chronic obstructive pulmonary disease (COPD) using the FULFIL trial: a UK perspective. Respir Med. 2019;1:100008.
  • Exuzides A, Colby C, Briggs AH, et al. Statistical modeling of disease progression for chronic obstructive pulmonary disease using data from the ECLIPSE study. Med Decis Making. 2017;37(4):453–468. doi:10.1177/0272989X15610781
  • Briggs AH, Baker T, Risebrough NA, et al. Development of the Galaxy chronic obstructive pulmonary disease (COPD) model using data from ECLIPSE: internal validation of a linked-equations cohort model. Med Decis Making. 2017;37(4):469–480. doi:10.1177/0272989X16653118
  • Tabberer M, Gonzalez-McQuire S, Muellerova H, et al. Development of a conceptual model of disease progression for use in economic modeling of chronic obstructive pulmonary disease. Med Decis Making. 2017;37(4):440–452. doi:10.1177/0272989X16662009
  • Risebrough NA, Briggs A, Baker TM, et al. Validating a model to predict disease progression outcomes in patients with COPD. Value Health. 2014;17(7):A560–561. doi:10.1016/j.jval.2014.08.1852
  • Worsley S, Snowise N, Halpin DMG, et al. Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design. ERJ Open Res. 2019;5(4):00061–02019. doi:10.1183/23120541.00061-2019
  • Jones P, Shukla S, Tombs L, et al. Predicting SGRQ score based on CAT score: post-hoc analysis of the IMPACT trial. Paper presented at: European Respiratory Society Congress; 2021; Barcelona, Spain.
  • Starkie HJ, Briggs AH, Chambers MG, Jones P. Predicting EQ-5D values using the SGRQ. Value Health. 2011;14(2):354–360. doi:10.1016/j.jval.2010.09.011
  • BNF. British National Formulary; 2020. Available from: https://bnf.nice.org.uk/. Accessed September 28, 2022. 15, 2021.
  • NICE. Chronic obstructive disease in over 16s: diagnosis and management. Economic model report; 2018. Available from: https://www.nice.org.uk/guidance/ng115/documents/economic-report. Accessed September 15, 2021.
  • ONS. Office of National Statistics (ONS). Consumer price index; 2020. Available from: https://www.ons.gov.uk/economy/inflationandpriceindices/timeseries/l522/mm23. Accessed September 15, 2021.
  • NICE. Guide to the methods of technology appraisal; 2013. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed August 2, 2021.
  • Bakerly ND, Browning D, Boucot I, et al. The impact of fluticasone furoate/vilanterol on healthcare resource utilisation in the Salford Lung Study in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2021;15:17534666211001013. doi:10.1177/17534666211001013
  • Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169(3):219–229. doi:10.1001/archinternmed.2008.550

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.